Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Chun-Yu LiuKa-Yi LauChia-Chi HsuJi-Lin ChenChia-Han LeeTzu-Ting HuangYi-Ting ChenChun-Teng HuangPo-Han LinLing Ming TsengPublished in: PloS one (2017)
Our study provided a preclinical rationale in selecting patients who might have therapeutic benefit from combining CDK4/6 inhibitors with AR antagonists.